Zacks Research Downgrades Theravance Biopharma (NASDAQ:TBPH) to Hold

Theravance Biopharma (NASDAQ:TBPH) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research restated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. HC Wainwright increased their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, B. Riley Financial increased their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.49 on Monday. The firm’s 50 day moving average price is $16.42 and its 200-day moving average price is $17.50. The company has a market cap of $850.06 million, a PE ratio of 7.50 and a beta of 0.17. Theravance Biopharma has a 52-week low of $10.42 and a 52-week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, analysts forecast that Theravance Biopharma will post 1.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new stake in Theravance Biopharma during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its holdings in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.